Delivery Order SPE2DB22D3004-SPE2DB25FQ83S
- Not listed
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $22,349.60 for 200-unit vials of Xeomin on August 26, 2025, with an ultimate completion date of September 17, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The contract represents a discrete fulfillment against AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a $11,174.80 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Xeomin 200 Unit Vials, with completion scheduled for August 8, 2025. This competitively awarded contract, issued without set-aside designation, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of Xeomin 100 Unit Vials, with a ceiling value of $5,989.62 and an ultimate completion date of October 9, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under an open procurement process. The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania, where the company serves as a...
- The Defense Logistics Agency awarded a delivery order valued at $23,467.08 to AmerisourceBergen Drug Corp for the supply of Xeomin 100 Unit Vials, with an ultimate completion date of September 19, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The work will be performed at AmerisourceBergen's...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Xeomin 50 unit vials valued at $10,941.84. This competitively awarded, non-set-aside contract is structured as a firm fixed price delivery order with a completion date of September 10, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. The delivery order falls under the...
- The Defense Logistics Agency awarded a $9,118.20 firm fixed price delivery order to AmerisourceBergen Drug Corp on June 18, 2025, for the supply of Xeomin 50 Unit Vials, with an ultimate completion date of July 11, 2025. This non-set-aside contract is a child delivery order executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999.00 and extends through December 2026. The pharmaceutical distributor,...
- The Defense Logistics Agency awarded a $46,934.16 delivery order to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin on July 18, 2025, with an ultimate completion date of August 8, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at...
- The Defense Logistics Agency awarded a delivery order valued at $2,793.70 to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin, a botulinum toxin product used for medical and therapeutic purposes. The contract, awarded on August 12, 2025, with an ultimate completion date of September 3, 2025, represents a firm fixed-price delivery order with no set-aside designation. Performance will occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of Xeomin 100 Unit Vials, with a ceiling value of $23,467.08 and a firm fixed price structure. This is a non-set-aside, competitively awarded contract with an ultimate completion date of October 9, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its Corporate Office location. This...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $2,793.70 firm fixed-price delivery order for 100-unit vials of Xeomin on July 11, 2025, with an ultimate completion date of August 1, 2025. The order will be fulfilled at the company's corporate office location in Conshohocken, Pennsylvania. This competitively awarded delivery order carries no set-aside designation and represents a child contract under AmerisourceBergen's larger federal contract portfolio with the DLA. This...
- SPE2DB22D3004Indefinite Delivery Contract
- SPE2DB22D3004-SPE2DB25FQ83SDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Xeomin 100 unit vials, valued at $23,467.08, with an ultimate completion date of October 14, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's Conshohocken, Pennsylvania location. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems through the DLA Medical Supply Chain. This delivery order is issued under AmerisourceBergen Drug Corp's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. This prime contract vehicle enables the company to supply a comprehensive range of pharmaceutical products and medical supplies supporting military healthcare programs globally. Xeomin, a botulinum toxin product used in medical and therapeutic applications, represents one of the specialized pharmaceutical commodities available through the broader contract framework. The company's proven capability in meeting federal medical supply requirements through competitive awards demonstrates its role as a key supplier to the Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $23.5k | 9/22/25 |